ST-503 will be evaluated in a phase 1/2 trial with the first patient scheduled to receive the therapy in the coming months. The Food and Drug Administration (FDA) has granted Fast Track designation to ...

Small fiber neuropathy (SFN) is a chronic and debilitating condition caused by damage to peripheral sensory nerves, which are responsible for pain, temperature sensation and autonomic functions.

Sangamo Therapeutics Inc. has received IND clearance from the FDA for ST-503, an investigational epigenetic regulator for the treatment of intractable pain due to idiopathic small fiber neuropathy ...

Please provide your email address to receive an email when new articles are posted on . The FDA has cleared an investigational new drug application for an epigenetic regulator to treat intractable ...

FDA IND clearance enables a phase 1b evaluation of SP16 in chemotherapy-induced pain and peripheral neuropathy, with enrollment planned for mid-2026 at the University of Virginia. Proposed mechanisms ...

Gregory Maassen, a man afflicted with a form of peripheral neuropathy, is currently e-biking across America to raise ...

Peripheral neuropathy affects millions of people and can cause symptoms ranging from tingling and burning sensations to numbness and balance problems. According to experts at Advanced Neuropathy ...